| Gene name: | TP53 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | PA-1(ATCC) |
| Experiment: | Western blot//SA-β-gal activity assay//Cell morphological analysis |
| Description: | We found that an increase in p16INKA4A expression was detected from days 4 5 post-treatment in TP53-silenced cells, corresponding with the partial release from G2 arrest and increase in (aberrant) mitoses.In control cells, ETO treatment evoked a modest but measurable increase in cell size (hypertrophy) and weak sa-β-gal staining at later time points. However, this was greatly accelerated by the silencing of TP53 with strong sa-β-gal staining in a significantly (p < 0.05, n = 3) higher proportion of cells in TP53-silenced (mean = 70.7%) vs. control (mean = 38.7%) samples at day 5 post-treatment. |
| Target gene: | OCT4A//P21 |
| Official symbol(s): | POU5F1//P21 |
| R-AG-Target gene: | --//-- |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot |
| Target gene description: | Transfection of PA-1 cells with TP53-siRNA successfully silenced TP53 expression throughout the time-course and, as expected, inhibited the increase in P21CIP1 in response to ETO treatment. However, unexpectedly, silencing of TP53 also largely inhibited the upregulation of OCT4A. To confirm this surprising finding, we repeated these experiments using PA-1 cells stably transfected with a shRNA vector directed against a different region of TP53 and saw the same results with diminished OCT4A upregulation. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...